Skip to main content
. 2021 Sep 16;12:739048. doi: 10.3389/fimmu.2021.739048

Figure 4.

Figure 4

Potential clinical therapeutics targeting SIRPs and CD47 for type 1 diabetes prevention or suspension. Immunotherapies could be utilized to increase the expression of SIRPγ and/or CD47 on primary T cells for adoptive cell therapies or CD47 on stem cell-derived β-cells or islets before transplant to attenuate the magnitude of recurrent autoimmunity. Red Text Box: Expected Decrease; Green Text Box: Expected Increase.